SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment
The SURGE study is testing a behavioral intervention to help more people from underrepresented groups learn about and decide on genomic testing for their cancer. Genomic testing looks at the genes in your tumor and can help doctors find personalized treatments or clinical trials. This study uses a video, sometimes with one-on-one guidance, to help you understand genomic testing. We want to see if this helps more people get genomic testing. You might be able to join if you are an adult (18 or older) who is Black, Latinx, or over 70, and have gastrointestinal, hematologic (blood), or thoracic (chest) cancer that needs treatment. The study aims to enroll 210 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention. It aims to enroll 210 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Genomic testing uptake will be measured up to 90 days after enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
At a glance
Conditions
Where it's being run
3 sites across 1 statesStudy leadership
- Nadine J McCleary, MD MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Genomic testing uptakeUp to 90 days of enrollment
Intervention impact on rate of uptake of genomic testing